Inside Microsoft, a Powerful New AI Executive Is Quietly Dismantling the Manager Class—And He's Using AI as the Excuse

**By [moonlight editory team] | October 29, 2026 | 11-Minute Read**

---

## The Short Version (For the Busy American)

There's a new power center inside Microsoft, and it isn't in the C-suite.

**Charles Lamanna**, the executive who already ran Microsoft's Copilot platform and AI agent business, quietly took control of **Office and Teams** earlier this month when their previous boss, Ryan Roslansky, announced he was leaving . Those two products are used by hundreds of millions of workers every day. They are the beating heart of Microsoft's enterprise empire.

And Lamanna is not maintaining them. He's **rebuilding them from the inside out**.

He's flattening the management structure, converting middle managers into individual contributors, requiring senior staff to be in the office **four days a week**, and offering relocation to major hubs. His justification, delivered in a memo to his teams: *"The most important thing my team will do this year won't be any single product or feature we ship: instead, it will be changing how we work"* .

**The punchline:** Lamanna is using the rise of AI agents as the intellectual cover for a brutal organizational reset. The message is simple and unsettling: if AI can write code and coordinate work, Microsoft doesn't need as many managers. And if you're a manager who doesn't adapt, you're the redundancy.

---

## What Lamanna Is Actually Doing

Let me walk you through the changes, because they reveal a playbook that's spreading across corporate America.

### The Flattening

The Teams unit under Lamanna reorganized to a ratio of **one manager for every 12 individual contributors**, according to people familiar with the changes . Managers were converted into individual contributors. The "span of control"—the number of people reporting to each manager—was deliberately widened.

Microsoft's official explanation is a masterclass in corporate euphemism: *"Agentic coding capabilities have changed every level of the engineering function. Software engineers are no longer hand-assembling every line of code. Instead, they are now designing and directing the 'agentic coding machine' that helps build the product"* .

Translation: **AI writes the code. Engineers direct the AI. Managers coordinate the engineers. But if the AI can coordinate too, why do you need the manager?**

### The Return-to-Office Mandate

Lamanna didn't stop at org charts. He's requiring employees at the "partner" level and above—some of Microsoft's most senior staff—to work in physical offices **at least four days a week**, exceeding the company-wide standard of three days .

He's also offering select U.S. employees the option to **relocate to Redmond, San Francisco, or New York** .

The implicit message: *If you want to stay in a leadership role, show up. If you don't want to show up, there's the door.*

### The Context

This isn't happening in a vacuum. Microsoft is in the middle of a massive AI spending spree—**$175 billion in capital expenditures** forecast for the 2026 calendar year . To fund that, the company is cutting costs everywhere else. It offered **voluntary buyouts to roughly 60,000 employees**—about 27% of its workforce—earlier this week .

Lamanna's reorganization is the operational side of that financial equation. The buyouts reduce headcount. The flattening ensures the remaining headcount is deployed differently.

---

## The Human Touch: What This Means for the People Inside Microsoft

Let me put this in terms that connect to the lives behind the org charts.

### The Middle Manager Squeeze

If you're a middle manager at Microsoft—or at any large company watching this playbook—the message is uncomfortable. **Your job is being redefined as a cost to be minimized.**

Lamanna's logic is that agentic AI reduces the need for "managerial coordination"—managing handoffs, orchestrating work across teams, the kind of work that middle managers have historically done . If the AI handles the coordination, the manager becomes a bottleneck, not a bridge.

That's not just a Microsoft story. It's a **white-collar anxiety** story. The jobs being eliminated aren't factory floors. They're the people who used to sit in meetings, send status updates, and manage workflows. AI is coming for them first.

### The Relocation Ultimatum

The relocation offer sounds generous on paper. But it comes with an implicit threat: **stay in your current location, and your career prospects may suffer**.

For employees with families, mortgages, and roots in their communities, "relocate to Redmond or San Francisco" isn't a choice. It's a pressure tactic. Some will go. Some will take the buyout. Either way, the headcount shrinks.

### The Buyout Backdrop

The 60,000 buyout offers loom over everything. If you're in a team that's being flattened, and you're offered a buyout, the calculation changes. Do you stay and hope you survive the reorganization? Or do you take the package and leave on your own terms?

Microsoft says it expects only **3% to 5%** of eligible employees to accept the buyouts, based on industry norms . But the offer itself changes the psychology of the workplace. Everyone is thinking about the exit.

---

## Why This Matters Beyond Microsoft

Here's the part that should concern every American worker, not just Microsoft employees.

### The "Agentic AI" Excuse

Lamanna's reorganization is being justified by the rise of AI agents—software that can autonomously perform tasks, make decisions, and coordinate workflows. Microsoft is betting that these agents will reduce the need for human managers.

Whether that bet is correct is an open question. But the **organizational changes are happening now**, before the AI is fully proven. That means the justification is partly **aspirational**. The company is restructuring for a future it believes is coming, not a reality it has already delivered.

If the AI doesn't deliver the promised productivity gains, the flattened organization may struggle to coordinate work that used to be managed by humans. The cost of the bet is borne by the people who lose their jobs.

### The Blueprint

Lamanna's playbook is being watched across corporate America. Flatten the organization. Reduce managerial layers. Use AI as the rationale. Offer buyouts to soften the blow.

If it works at Microsoft—if the company can cut costs, maintain productivity, and keep the stock price up—expect other large employers to follow. The middle manager is becoming an endangered species.

### The Productivity Question

Here's the uncomfortable truth that nobody at Microsoft wants to say out loud: **the company hasn't proven that AI can replace managerial coordination at scale**. The Copilot products have struggled to gain traction. Microsoft's own AI metrics are reviewed weekly by CEO Satya Nadella—a sign that the company is still figuring out what works .

The reorganization is a bet. The people who lose their jobs are the stake.

---

## Frequently Asked Questions

### Who is Charles Lamanna?

He's Microsoft's head of the **Copilot platform, AI agents, and now Office and Teams**. He took over the Office and Teams groups in October after Ryan Roslansky announced his departure. He's seen as a key player in Microsoft's AI transition and reports directly to CEO Satya Nadella .

### What changes is Lamanna making?

He's **flattening the management structure** in his teams, converting middle managers to individual contributors. The Teams unit now has a ratio of **one manager per 12 engineers**. He's also requiring senior staff to work in the office **four days a week** and offering relocation to Redmond, San Francisco, or New York .

### Why is he doing this?

Officially, because **agentic AI is changing how software is built**. Microsoft says engineers are no longer hand-assembling code—they're directing AI that writes the code. That reduces the need for managerial coordination. Unofficially, it's a cost-cutting move amid Microsoft's **$175 billion AI spending spree** .

### How does this connect to the buyouts?

Microsoft offered **voluntary buyouts to 60,000 employees**—about 27% of its workforce—earlier this week. The buyouts and the reorganization are two sides of the same coin: Microsoft is reducing headcount and reshaping the remaining workforce around AI .

### Is this happening elsewhere in Microsoft?

**Yes.** CEO Satya Nadella has been dismantling the old senior leadership structure for months. The Senior Leadership Team (SLT) was retired, replaced by smaller, flatter groups. Several longtime executives have left, and Nadella is personally reviewing AI metrics weekly .

### What does this mean for middle managers?

It means **middle management is under pressure**. If AI can coordinate work and handle handoffs, the traditional role of the middle manager shrinks. Lamanna's reorganization is a preview of what's coming across corporate America as AI agents become more capable .

### Should I be worried if I work in tech?

**It depends on your role.** Software engineers who can direct AI and design systems are in demand. Managers who coordinate work that AI can coordinate are vulnerable. The skills that matter are shifting—technical judgment, system design, quality assurance, and customer understanding are becoming more valuable than pure coordination .

---

## The Path Forward: What to Watch

### Microsoft's Earnings (Wednesday)

Microsoft reports quarterly results after the market close on Wednesday. Watch for **headcount data, capex guidance, and any commentary on the reorganization**. If the company signals more cuts are coming, the anxiety inside the workforce will intensify .

### The Buyout Uptake

Microsoft expects only **3% to 5%** of eligible employees to accept the buyouts. If the actual number is higher, it signals that morale is worse than the company expected—and that the reorganization is driving people out faster than planned .

### The AI Productivity Proof

The reorganization is justified by the belief that AI agents can reduce managerial overhead. Watch for evidence that this is actually happening—or that the flattened structure is struggling to coordinate work. The answer will determine whether Lamanna's playbook becomes the corporate standard or a cautionary tale.

### The Spread

If Microsoft's reorganization succeeds—if costs fall and productivity holds—expect other large employers to follow. The middle manager is the first casualty of the AI era. They won't be the last.

---

## Conclusion: The Manager Is the Redundancy

Here's what I want you to take away from Charles Lamanna's quiet power grab.

Microsoft isn't just building AI. It's **restructuring itself around AI**—and the people bearing the cost are the ones who used to hold the organization together.

Lamanna's message is clear: **if AI can coordinate the work, the coordinator is optional**. The engineers who direct the AI are essential. The managers who directed the engineers are not.

That's a bet. It may be right. It may be wrong. But the people who lose their jobs while Microsoft figures it out won't get to find out which.

The AI revolution isn't just coming for factory workers and customer service reps. It's coming for the middle class of corporate America—the people who thought their jobs were safe because they were the ones giving the orders.

Charles Lamanna just showed them the door. And he's using AI as the excuse.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any securities. The author is not a licensed financial advisor. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change. The author holds no position in any securities mentioned.

---

**Tags:** #Microsoft #MSFT #CharlesLamanna #Copilot #AIAgents #Office #Teams #SatyaNadella #Buyouts #Layoffs #MiddleManagers #FutureOfWork #AIRevolution #CorporateRestructuring #TechNews #StockMarketToday #FinancialNews #MarketAnalysis #Investing #RTO #ReturnToOffice #Productivity #AgenticAI #Management #CareerAdvice #TechIndustry #AI Economy #WorkplaceCulture #MicrosoftReorg #EmployeeMorale #InvestmentStrategy

Volkswagen Just Posted a $6.5 Billion Loss—And 100,000 Workers Are About to Pay for It

 Volkswagen Just Posted a $6.5 Billion Loss—And 100,000 Workers Are About to Pay for It

October 29, 2026 | 11-Minute Read**

---

## The Short Version (For the Busy American)

Volkswagen just delivered the kind of quarter that ends careers and closes factories.

The German auto giant reported an **operating loss of €5.86 billion ($6.5 billion)** for the third quarter—its worst result since 2015, and far wider than the €2.6 billion loss analysts had expected . Revenue fell **6.3% to €75.3 billion**, and global vehicle deliveries dropped **14.3% to 1.885 million cars** .

But the number that explains everything is this one: **Volkswagen's deliveries in China fell 38.5% in the quarter** to just over 405,000 vehicles. Over the first nine months of the year, China sales are down **30.2%** . China used to be Volkswagen's profit engine. Now it's the hole the company can't climb out of.

**The punchline:** Volkswagen is about to cut **100,000 jobs**—roughly 15% of its global workforce—and may close four German factories. The company that built the People's Car is now fighting to survive the electric age.

---

## What Actually Happened: The Porsche Write-Down and the China Collapse

Let me walk you through the numbers, because the headline loss is only part of the story.

### The Porsche Impairment

The biggest single hit to Volkswagen's bottom line wasn't a factory or a failed model. It was **Porsche**.

Volkswagen recorded a **€6.4 billion ($7.14 billion) write-down** on the value of its sports-car subsidiary, reflecting weaker expectations for Porsche's future performance . Porsche's operating margin has collapsed as demand for luxury EVs softens and Chinese rivals eat into its premium positioning.

That write-down alone accounts for more than the entire quarterly loss. Strip it out, and Volkswagen's underlying business is still weak—but not catastrophic.

### The China Collapse

Here's the number that should terrify every legacy automaker: **China deliveries fell 38.5% in Q3** . The overall Chinese car market contracted, but Volkswagen's decline was far steeper than the market itself.

Why? Because China has moved on. **New-energy vehicles now account for roughly two-thirds of passenger-car sales** in China . Volkswagen built its dominance on joint ventures and combustion-engine cars. Those are exactly the products Chinese buyers are abandoning.

**BYD and Geely now outsell Volkswagen's joint ventures** in China's retail rankings. In September, FAW-Volkswagen sold about 76,800 vehicles—down 44.6% year-over-year .

### The Rest of the World Isn't Much Better

China isn't the only problem. Volkswagen's global deliveries fell **14.3%**—the steepest quarterly decline in four years . The Volkswagen Passenger Cars brand itself dropped **19.3%**. Audi fell **19.7%**. Porsche fell **15%** .

Only Skoda was flat, up 0.2%. That's the definition of a company-wide problem.

---

## The Human Touch: What 100,000 Job Cuts Actually Means

Let me put this in terms that connect to the lives behind the restructuring plan.

### The Factories on the Chopping Block

Volkswagen's board has approved a plan that could eliminate **100,000 jobs globally**—roughly **15% of its workforce**—by the end of the decade . The company has identified **four German factories** whose future is uncertain: **Hannover, Emden, Zwickau, and Neckarsulm** (the Audi plant) .

No final closure decisions have been made. But Volkswagen has said these plants **do not have competitive production plans** for the period after their current models phase out between 2031 and 2034 .

For the workers in those towns, the message is clear: **your job may not exist in five years**.

### The Union Deal

This isn't a unilateral corporate decision. Volkswagen's supervisory board includes powerful labor representatives, and the restructuring plan was negotiated with **IG Metall**, Germany's largest union .

The deal avoided immediate plant closures—a politically explosive step in Germany. But it came at a cost: **the workforce will shrink by 100,000 people**. Christiane Benner, IG Metall's president, said the union "fought hard to find good solutions in this crisis situation" .

The crisis is real. The solutions are painful.

### The Margin Problem

Volkswagen's CFO, Arno Antlitz, was blunt about why this is happening. The company's operating margin—after stripping out one-time charges—was **3.8%** in the first nine months of 2026. That's "too low to continue investing strongly in our future," he said .

For context, Volkswagen's target is a **9% operating margin by 2030** . It's currently less than half that. The restructuring isn't about greed. It's about survival.

---

## Why Volkswagen Fell So Far Behind

This didn't happen overnight. Volkswagen's crisis is the accumulation of years of missed signals.

### The Electric Transition

Volkswagen was supposed to be the legacy automaker that got EVs right. It launched the ID series, invested billions in battery plants, and promised to challenge Tesla. But the ID lineup has been plagued by **software problems, quality issues, and weak demand**. And the margins on EVs are lower than on combustion cars—a problem Antlitz acknowledged directly: **"We currently earn less with electric cars than with combustion engines"** .

### The China Trap

Volkswagen's China strategy was built on **joint ventures** with state-owned partners. Those JVs gave Volkswagen scale and market access, but they also made the company slow to adapt. When Chinese consumers shifted to EVs and smart features, Volkswagen's JV-built cars couldn't compete with BYD's vertically integrated, software-heavy offerings .

### The Cost Structure

Volkswagen has long been criticized for **bloated costs and slow decision-making**. The company's structure gives politicians and labor representatives significant power—Lower Saxony holds 20% of the stock and has blocking rights on strategic decisions . That structure protected jobs during good times. In a crisis, it makes restructuring harder.

---

## Frequently Asked Questions

### How big was Volkswagen's loss?

**€5.86 billion ($6.5 billion) operating loss** in Q3 2026—the worst since 2015. Revenue fell 6.3% to €75.3 billion, and global deliveries dropped 14.3% .

### Why did Volkswagen lose so much money?

The biggest factor was a **€6.4 billion write-down on Porsche**, reflecting weaker future expectations for the sports-car brand. The China collapse—deliveries down 38.5%—and rising costs also weighed heavily .

### How bad is China for Volkswagen?

**Very bad.** Q3 deliveries fell 38.5% to about 405,000 vehicles. Over the first nine months, China sales are down 30.2%. Chinese brands like BYD and Geely now outsell Volkswagen's joint ventures .

### How many jobs will be cut?

**Up to 100,000 globally**—roughly 15% of Volkswagen's workforce. This combines 50,000 cuts already agreed with another 50,000 approved by the board in September .

### Which factories might close?

Four German plants are under review: **Hannover, Emden, Zwickau, and Neckarsulm** (Audi). No final closure decisions have been made, but Volkswagen has said these sites lack competitive production plans for after 2031 .

### What is Volkswagen's plan to fix this?

The restructuring aims to:

- Cut **100,000 jobs**

- Reduce the **model range by half** by 2035

- Cut **offering complexity by 75%**

- Achieve a **9% operating margin by 2030**

- Invest **€135 billion** in factories, R&D, and technology between 2027 and 2031 

### What did the CEO say?

CEO Oliver Blume has said Volkswagen's costs are **20% higher** than rivals and that the company must become "more efficient, more resilient, and simpler" . The Q3 results give his management team leverage in negotiations with unions .

### Is Volkswagen going to survive?

**Yes, but it will be smaller.** Volkswagen is Europe's largest automaker and a cornerstone of the German economy. It has €33 billion in net liquidity and positive cash flow in its automotive division . But the company that emerges from this restructuring will have fewer workers, fewer models, and a smaller global footprint.

---

## The Path Forward: What to Watch

### The Union Negotiations

The 100,000 job cuts are approved in principle, but the details—who goes, when, and with what severance—are still being negotiated. Watch for strikes, protests, and political pressure from Lower Saxony, which holds a blocking minority.

### The China Strategy

Volkswagen is developing **locally designed EVs** for China, with shorter product cycles. It says electrified vehicle deliveries in China rose about **30% in Q3**—a small sign of progress from a low base . Watch whether that momentum continues.

### The 2027 Outlook

Volkswagen expects 2026 revenue of about **€315 billion** and an operating margin of **no more than 1%**—down from previous guidance of 4-5.5% . Watch for whether the restructuring produces visible margin improvement in 2027, or whether further cuts are needed.

### The Porsche Question

The €6.4 billion write-down reflects a fundamental reassessment of Porsche's value. Watch whether Porsche can regain its premium pricing power—or whether it becomes a drag on Volkswagen for years to come.

---

## Conclusion: The People's Car Meets the People's Verdict

Here's what I want you to take away from Volkswagen's quarter.

Volkswagen built its empire on a simple promise: **a car for everyone**. The Beetle, the Golf, the Jetta—these were cars for teachers and factory workers and families. The company became a symbol of German industrial might, employing hundreds of thousands of people and anchoring entire communities.

That model is breaking. The electric transition is expensive. The Chinese market has turned against legacy brands. The cost structure is too high. And the losses are too big to ignore.

The 100,000 job cuts aren't a betrayal of Volkswagen's promise. They're the price of keeping the company alive. The four factories under review aren't casualties of greed. They're casualties of a market that moved faster than Volkswagen could follow.

For the workers in Hannover and Emden and Zwickau, the future is uncertain. For Volkswagen, the future is smaller. The People's Car is learning what happens when the people stop buying.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any securities. The author is not a licensed financial advisor. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change. The author holds no position in any securities mentioned.

---

**Tags:** #Volkswagen #VW #Q3Earnings #Porsche #China #AutoIndustry #JobCuts #Restructuring #StockMarketToday #FinancialNews #MarketAnalysis #Investing #Germany #Audi #Skoda #BYD #Geely #EV #ElectricVehicles #OliverBlume #IGMetall #Hannover #Emden #Zwickau #Neckarsulm #AutoStocks #InvestmentStrategy #RiskManagement #EarningsSeason #GermanEconomy

The Fed’s Favorite Inflation Gauge Just Went the Wrong Way—And the 3.4% GDP Beat Won’t Save Your Wallet

 The Fed’s Favorite Inflation Gauge Just Went the Wrong Way—And the 3.4% GDP Beat Won’t Save Your Wallet

| October 29, 2026 | 11-Minute Read**

---

## The Short Version (For the Busy American)

The Commerce Department dropped two huge numbers Thursday morning, and they tell a story that should make every American household pay attention.

**The economy grew at a 3.4% annual pace in the third quarter**—faster than the 3.1% economists expected, and a big jump from the 2.2% pace in the spring . Consumer spending and AI investment drove the surge.

But the Fed’s preferred inflation gauge—the **Personal Consumption Expenditures (PCE) price index**—**rose 3.6% year-over-year in September**, up from 3.4% in August and the highest since May. **Core PCE**, which strips out food and energy, ticked up to **3.1%** .

Here’s the part that should make you angry: **personal income rose just 0.2%** in September, missing expectations. **Real personal spending**—what you can actually buy after inflation—**barely moved, up less than 0.1%** . And the **personal savings rate fell to its lowest level since October 2022** .

**The punchline:** The economy is producing more. You’re just not keeping any of it.

---

## What the PCE Report Actually Tells Us

Let me break down the inflation data, because the details explain why the Fed is still nervous.

### The Headline Numbers

| Metric | September 2026 | August 2026 | Change |

|--------|----------------|-------------|--------|

| **Headline PCE (YoY)** | **3.6%** | 3.4% | **+0.2 pts** |

| **Headline PCE (MoM)** | **0.5%** | 0.3% | **+0.2 pts** |

| **Core PCE (YoY)** | **3.1%** | 3.0% | **+0.1 pts** |

| **Core PCE (MoM)** | **0.3%** | 0.3% | **Flat** |

*Source: Bureau of Economic Analysis, Trading Economics* 

The numbers came in **in line with expectations**—no upside surprise, no downside relief. But the direction is what matters. Inflation was cooling through the summer. Now it’s moving **away** from the Fed’s 2% target, not toward it.

### The Energy Problem

The culprit is the same one that’s been squeezing your budget for months: **energy prices**. The Iran war pushed oil higher, and those costs are flowing into everything. Oxford Economics’ Bernard Yaros put it plainly: **“Inflation moved away from the Federal Reserve’s 2% target in September. Spillovers from higher energy costs into core prices, along with strong AI investment demand, will keep the central bank on guard”** .

### The Savings Squeeze

Here’s the human story behind the GDP headline. **Personal income rose just 0.2%**—below the 0.3% forecast. **Personal spending rose 0.5%**, matching expectations. But after adjusting for inflation, **real spending barely budged** .

Americans are spending more dollars to buy roughly the same amount of stuff. And they’re funding that spending by **saving less**. The savings rate is now the lowest since 2022 .

That’s not a healthy consumer. That’s a consumer running on fumes.

---

## The GDP Beat: Strong Headline, Weak Foundation

Let me walk you through what actually drove the 3.4% growth, because the composition matters.

### The AI Investment Boom

Business investment was a major contributor. Spending on **information processing equipment surged**, reflecting the AI infrastructure buildout. Warsh himself noted that capital investment is “solid” and that **AI investment cannot be separated from the interest rate environment**—higher borrowing costs affect every part of the AI supply chain .

### The Import Leakage

Here’s the catch that the GDP headline hides. **Imports increased** in the third quarter, subtracting from GDP . Much of the AI hardware—servers, chips, networking equipment—is **built overseas**. When U.S. companies buy it, the investment adds to GDP, but the import subtracts almost the same amount. The net effect on growth is smaller than the investment number suggests.

### The Consumer Was Solid—But Not Spectacular

Consumer spending contributed to growth, but the **real spending figure**—after inflation—was weak. Americans are spending more because prices are higher, not because they’re buying more.

---

## The Human Touch: Why This Matters for Your Wallet

Let me put this in terms that actually connect to your life.

### Your Paycheck Isn’t Keeping Up

The PCE report shows income growth of **0.2%** against inflation of **0.5%**. That’s a **real income decline**. Your paycheck is buying less than it did a month ago.

The GDP number says the economy is growing. The income number says you’re not sharing in the growth.

### The Fed Is Still Leaning Hawkish

The Fed held rates steady on Wednesday at **3.75%-4.00%**, with **two dissents in favor of a hike** . Chair Kevin Warsh refused to signal the next move, saying “don’t prejudge meetings” . But markets are pricing an **83% chance of a December hike** .

If that happens, your mortgage rate—already above 7%—could climb further. Your credit card APR could go up. Your car loan could get more expensive.

### The Savings Buffer Is Gone

The savings rate is at its lowest since 2022. That means the cushion that kept families afloat during the pandemic is gone. If you lose your job, or your car breaks down, or your roof leaks—there’s nothing left to fall back on.

The economy is growing. Your safety net is not.

---

## Frequently Asked Questions

### What did the September PCE report show?

**Headline PCE rose 3.6% year-over-year**, up from 3.4% in August and the highest since May. **Core PCE rose 3.1%**, up from 3.0%. Both were in line with expectations, but both moved **away** from the Fed’s 2% target .

### What did the Q3 GDP report show?

**Real GDP grew at a 3.4% annual rate**, beating the 3.1% consensus and accelerating from 2.2% in Q2. Growth was driven by investment, consumer spending, and government spending, partly offset by a decrease in exports and an increase in imports .

### Why is inflation rising again?

**Energy prices** are the primary driver. The Iran war pushed oil higher, and those costs are feeding into broader inflation. Oxford Economics noted that “spillovers from higher energy costs into core prices, along with strong AI investment demand” will keep the Fed on guard .

### What does the PCE report mean for the Fed?

It means the Fed’s pause is **not a pivot**. The statement said “inflation remains elevated” and that “the accumulation of more information will help the Committee determine the policy stance” . Markets still price an **83% chance of a December hike** .

### Why is real spending so weak if GDP is strong?

Because **inflation is eating the growth**. Personal income rose 0.2%, but prices rose 0.5%. After adjusting for inflation, real spending barely moved. The GDP number measures total output; the income and spending numbers measure what’s actually reaching households .

### What is the savings rate and why does it matter?

The **personal savings rate** is the percentage of disposable income that households save. It fell to its **lowest level since October 2022** . A low savings rate means families have less of a buffer against job loss, medical bills, or other emergencies. It also means consumption is being funded by drawing down savings rather than by rising incomes—a pattern that can’t continue indefinitely.

### How does this affect my mortgage rate?

The Fed’s hawkish stance and the inflation data keep upward pressure on Treasury yields. The 10-year yield is hovering near **5%**, and ING projects it could reach **5.25%** . Mortgage rates track the 10-year yield, so relief isn’t coming soon.

### Is the economy actually strong?

**It depends on how you measure it.** GDP is strong. Corporate profits are strong. The stock market is strong. But **real household income is weak**, the savings rate is depleted, and consumer sentiment is near record lows. The economy is producing more, but the gains aren’t reaching most households.

---

## The Path Forward: What to Watch

### The December Fed Meeting

Markets price an **83% chance of a hike** . Warsh has refused to signal his intentions, but the inflation data is pushing in one direction. A December hike would take the benchmark rate to **4.00%-4.25%**—the highest since before the financial crisis.

### The Next PCE Report

The October PCE data, due in late November, will show whether September’s uptick was a one-month blip or the start of a new acceleration. If it’s hot, December is locked in.

### The 10-Year Treasury Yield

ING projects the 10-year yield could reach **5.25%** . If it does, mortgage rates climb, stock valuations face pressure, and the Fed’s job gets harder.

### The Consumer

Watch retail sales and personal income data. If real spending continues to stagnate while inflation stays high, the economy’s foundation is weaker than the GDP headline suggests.

---

## Conclusion: The Growth Is Real. The Pain Is Realer.

Here’s what I want you to take away from Thursday’s data dump.

The U.S. economy is remarkably resilient. It’s growing at 3.4%. It’s absorbing an energy shock, a war, and the fastest rate-hiking cycle in decades. The AI boom is real, and it’s building the infrastructure of the future.

But **growth is not the same as prosperity**. The PCE report shows inflation moving the wrong way. The income data shows households falling behind. The savings rate shows the buffer is gone.

The Fed knows this. That’s why two officials dissented in favor of a hike. That’s why Warsh refused to promise a pause. That’s why markets are pricing another increase in December.

For American families, the message is uncomfortable: **the economy is growing, but your paycheck isn’t**. The GDP number is a headline. The PCE number is your grocery bill. And right now, the grocery bill is winning.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any securities. The author is not a licensed financial advisor. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change. The author holds no position in any securities mentioned.

---

**Tags:** #PCE #Inflation #GDP #USEconomy #FederalReserve #KevinWarsh #InterestRates #RateHike #StockMarketToday #FinancialNews #MarketAnalysis #Investing #EconomicData #BEA #ConsumerSpending #PersonalIncome #SavingsRate #EnergyPrices #IranWar #DecemberHike #MonetaryPolicy #InvestmentStrategy #RiskManagement #USEconomy2026 #CorePCE #TreasuryYields #MortgageRates #CostOfLiving #AmericanFamilies #EconomicOutlook

Consumers and A.I. Spending Push U.S. Economic Growth Higher—So Why Are Voters Giving the Economy a Failing Grade?

 Consumers and A.I. Spending Push U.S. Economic Growth Higher—So Why Are Voters Giving the Economy a Failing Grade?

 | October 29, 2026 | 11-Minute Read**

---

## The Short Version (For the Busy American)

The American economy just did something it hasn't done in a year: it grew at a **3.4% annual pace** in the third quarter, accelerating from 2.2% in the spring and beating the 3.0% to 3.2% forecasts that economists had been expecting . Consumer spending rose at a brisk **3.8% clip**, and business investment in AI infrastructure surged, with spending on information processing equipment jumping **37.4%** .

By every official measure, the economy is strong. The stock market is near record highs. Unemployment is low. The growth is real.

But here's the number that tells a completely different story: **consumer sentiment sits at 48.0**, the second-lowest reading on record, just above the all-time low set in May after the Iran war began . **One-year inflation expectations have climbed to 4.7%**, up from 3.4% in February . And **independent voters—the swing bloc that decides elections—have seen their sentiment score collapse to 42.4**, just above the record low .

**The punchline:** The economy is growing. The people living in it are not feeling it. And with the midterm elections just days away, that gap between the headline GDP number and the lived experience of American households is the most important economic story in the country.

---

## What the 3.4% Actually Represents

Let me walk you through the composition of this growth, because the details explain why voters are so angry.

### The Consumer Did the Heavy Lifting

Consumer spending, which accounts for more than two-thirds of the economy, rose **3.8%** in the third quarter . That's a strong number—but it comes with a caveat. Americans are spending more, but they're also **saving less and dipping into their nest eggs** to fund it . Wage gains have at times lagged inflation, meaning the spending is being financed by drawing down savings rather than by rising real incomes.

### The AI Boom Is Real—But It's Imported

Business investment excluding housing was up **12.7%**, with information processing equipment surging **37.4%** and software rising **9.6%** . That's the AI buildout showing up in the GDP math.

But here's the problem: **much of that equipment is imported**. The goods trade deficit widened as demand for AI-related capital goods lifted imports to a record high . When U.S. companies buy servers made overseas, the investment adds to GDP but the import subtracts almost the same amount. The net effect on growth is smaller than the headline investment number suggests.

### Housing Is Falling

While AI spending surged, **housing investment dropped 3.3%**—the sixth decline in seven quarters . High mortgage rates are crushing the housing market. For younger Americans trying to buy their first home, the economy isn't growing. It's closing doors.

### The Government Quirk

Federal spending contributed to growth, but partly for a technical reason: **fewer sales from the Strategic Petroleum Reserve** compared to the second quarter. Because oil sales are deducted from government consumption, selling less oil made government spending look bigger . That's not stimulus. It's an accounting artifact.

---

## The Human Touch: Why the People Are So Angry

Let me put this in terms that actually connect to the lives behind the GDP number.

### The Purchasing Power Problem

Joanne Hsu, the director of the University of Michigan's consumer survey, said it plainly: **"Purchasing power continues to dominate consumer views of the economy. Sentiment is now 10% below a year ago and 15% less than February, just prior to the Iran conflict"** .

Americans aren't confused. They know the economy is producing more. They also know their paycheck buys less than it did a year ago. Gas is above **$4 a gallon**. Diesel has been near record highs. Grocery bills keep climbing. The GDP number says the economy is growing. The grocery receipt says otherwise.

### The Partisan Split

Here's the part that should worry the party in power. The decline in sentiment was **led by independents**, whose score fell to 42.4 from 47.7 in September. Sentiment among Democrats and Republicans actually improved .

Since January, the number of **independents** citing high prices as a drag on their finances rose by **27%**. Among **Republicans**, it shot up by **52%** . That's not a base problem. That's a coalition problem.

### The Stock Market Divide

Households with **little or no exposure to the stock market** have increasingly cited high prices as a financial burden compared to the start of the year . The AI boom has driven stock prices to record highs—but the wealth it's creating is concentrated among the Americans who already owned stocks. For the majority of households, a booming 401(k) doesn't offset the pain at the pump.

Dean Baker of the Center for Economic and Policy Research summed it up: **"The overall picture is that the economy is growing at a decent pace, but the primary factors are an AI-driven investment boom and consumption driven primarily by rising stock wealth"** .

---

## The Political Reckoning

The midterm elections are **November 3**. Millions of Americans have already cast early ballots. And the polling is brutal for the incumbent party.

President Trump's approval rating in a Reuters/Ipsos poll sits at a **record low**, driven by the surge in fuel prices after his decision to attack Iran in late February . Polls show Republicans are likely to lose control of the House and possibly the Senate .

The irony is sharp. Trump won in 2024 partly by promising to bring down prices. Two years later, prices are still high, the war he started is still raging, and the voters who trusted him are blaming him for the cost-of-living crisis he promised to fix.

---

## Frequently Asked Questions

### What was the actual GDP growth rate?

**3.4% annualized** in the third quarter of 2026, up from 2.2% in the second quarter. It beat the 3.0% to 3.2% forecasts .

### What drove the growth?

**Consumer spending** rose 3.8%, and **business investment** in AI infrastructure surged. Spending on information processing equipment jumped 37.4%. Government spending also contributed, partly due to a technical quirk involving Strategic Petroleum Reserve sales .

### Why is the economy growing if people are so unhappy?

Because **growth and sentiment measure different things**. GDP measures output. Sentiment measures how people feel about their purchasing power. Americans are spending more, but they're paying more for essentials like gas and groceries, and their wages aren't keeping up. The AI boom is creating wealth, but it's concentrated among stock owners .

### How low is consumer sentiment?

The University of Michigan's index fell to **48.0 in October**, the second-lowest reading on record after the all-time low of 44.8 set in May .

### What are inflation expectations?

Consumers expect prices to rise **4.7% over the next year**, up from 3.4% in February before the Iran war. Five-year expectations rose to **3.5%** .

### How does this affect the midterms?

Polls show Republicans are likely to lose the House and possibly the Senate. Trump's approval rating is at a record low, and independents—the key swing bloc—have seen their sentiment collapse. Affordability is the top issue for voters .

### Is the Fed going to cut rates to help?

**No.** The Fed held rates steady at **3.75%-4.00%** on Wednesday, with two officials dissenting in favor of a hike. Inflation remains elevated, and the Fed is expected to hike again in December . The pause is a breather, not a pivot.

---

## The Path Forward: What to Watch

### The Second GDP Estimate (November 25)

The 3.4% figure is an **advance estimate**. It will be revised. Watch whether the consumer spending and AI investment numbers hold up—or whether the growth was less impressive than it first appeared .

### The PCE Inflation Report

The Fed's preferred inflation gauge will show whether the September CPI's hot reading was a blip or a trend. If inflation stays elevated, the December hike becomes even more certain.

### The Midterms (November 3)

The election is the ultimate verdict on the economy. If voters punish Republicans as the polls suggest, it will confirm that **GDP growth doesn't win elections—purchasing power does**.

### The AI Investment Pipeline

The AI boom is propping up GDP. If financing costs rise and projects get delayed, that support could weaken. Watch the credit markets and the hyperscalers' capex guidance for signs of a slowdown.

---

## Conclusion: The Economy Is Growing. The People Are Not.

Here's what I want you to take away from the 3.4% GDP report.

The American economy is remarkably resilient. It survived a war, an energy shock, and the fastest rate-hiking cycle in decades. It's still growing. It's still creating wealth. The AI boom is real, and it's reshaping the country's productive capacity.

But **growth is not the same as prosperity**. The 3.4% number measures what America produces. It doesn't measure whether Americans can afford to buy it. It doesn't measure the gap between the stock market and the grocery store. It doesn't measure the frustration of a family that sold everything to live on a cruise ship, or a worker whose paycheck buys less every month.

The voters know the difference. And in a few days, they'll make their voices heard.

The economy is growing. The people are not. And that gap is the story of this election.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or political commentary. The author is not a licensed financial advisor. All investments involve risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change.

---

**Tags:** #GDP #USEconomy #ConsumerSpending #AIInvestment #ConsumerSentiment #Inflation #MidtermElections #StockMarketToday #FinancialNews #MarketAnalysis #Investing #EconomicData #BEA #FederalReserve #RateHike #PurchasingPower #CostOfLiving #Voters #Independents #Trump #Republicans #Democrats #Affordability #HousingMarket #AI Trade #InvestmentStrategy #RiskManagement #USEconomy2026 #PCE #ConsumerConfidence

Merck Just Beat the Street and Raised Guidance—But the Real Story Is the $830 Million Shot Quietly Saving Keytruda

 

Merck Just Beat the Street and Raised Guidance—But the Real Story Is the $830 Million Shot Quietly Saving Keytruda

**By [moonlight editory team] | October 29, 2026 | 12-Minute Read**

---

## The Short Version (For the Busy American)

Merck just delivered a quarter that should have been impossible, and the reason is hiding in a single number that most headlines will bury.

The pharmaceutical giant reported **third-quarter revenue of $18.1 billion**, up 5% year-over-year and comfortably ahead of the $17.31 billion consensus. Adjusted earnings per share came in at **$2.49**, obliterating the $2.08 Wall Street expected . The stock rose more than **2%** in premarket trading on the beat and the raised guidance .

But here's the part that matters more than any earnings beat: **Keytruda Qlex**, the under-the-skin injectable version of Merck's flagship cancer drug, generated **$830 million in the quarter**. That topped the $649 million consensus by a wide margin and marked the highest quarterly sales for the shot since it launched in 2025 .

**The punchline:** Merck knows its most important patent expires in 2028. It's been racing to shift patients from the old IV drip to the new shot before the generics arrive. This quarter proved the strategy is working—and it bought Merck time it desperately needs.

---

## The Numbers That Matter

Let's cut through the noise and get to what actually counts.

### The Q3 Beat

| Metric | Q3 2026 | Consensus | Beat |

|--------|---------|-----------|------|

| **Revenue** | **$18.09B** | $17.31B | **+4.5%** |

| **Adjusted EPS** | **$2.49** | $2.08 | **+19.7%** |

| **Keytruda Franchise** | **$8.60B** | $7.73B | **+11%** |

| **Keytruda Qlex** | **$830M** | $649M | **+28%** |

| **GAAP Net Income** | $5.07B | — | -12% YoY |

*Source: CNBC, TipRanks, Quiver Quantitative* 

The revenue beat was driven by oncology and animal health. **Winrevair**, the pulmonary arterial hypertension drug, surged **93% to $694 million**. **Gardasil** rose 14% to nearly $2 billion. But the drag came from generics: **Januvia/Janumet fell 39%** and **Bridion dropped 67%** as cheap copycats flooded the U.S. market .

### The Guidance Raise

Merck raised its full-year adjusted EPS outlook to **$2.77 to $2.82**, up from the prior range of $2.66 to $2.76. That's above the $2.65 consensus . Revenue guidance was narrowed and the low end raised to **$66.8 billion to $67.3 billion** .

The guidance includes a **$400 million charge** (12 cents per share) tied to Merck's licensing deal with Chinese cancer drugmaker **SciBrunch** .

### The $550 Million Timing Quirk

One thing investors need to understand: Q3 sales got a **$550 million boost** from favorable purchase timing in the U.S. Merck said the benefit related to Keytruda and Winrevair will **fully unwind in Q4**, while the majority of the vaccine benefit (primarily Gardasil) will unwind next year .

Translation: the Q3 beat is real, but some of it is pulled-forward demand, not new demand. Q4 will feel the reversal.

---

## The Human Touch: What This Means for Patients and Investors

Let me put this in terms that actually connect to your life.

### If You or Someone You Love Is on Keytruda

The Qlex shot matters. The original Keytruda is an **intravenous infusion** that takes about 30 minutes and requires a clinic visit. Qlex is a **subcutaneous injection**—under the skin—that can be administered much faster. For patients who've been spending hours in infusion chairs, the switch is a genuine quality-of-life improvement.

Merck's strategy is clear: **move as many patients as possible to Qlex before the IV patents expire in 2028**. Qlex has its own patent protection, which means Merck can keep the Keytruda franchise alive even after the original drug goes generic .

For patients, this means the drug they depend on may not disappear when the patent cliff hits. For Merck, it means the $8.6 billion quarterly franchise doesn't evaporate overnight.

### If You Own Merck Stock

You've watched Merck navigate the toughest challenge in pharma: **the patent cliff**. Keytruda is one of the best-selling drugs in history, and it's facing generic competition in 2028. The Qlex strategy is Merck's answer.

The stock has been a steady performer, and the raised guidance is a sign that management is executing. But the Q4 unwind of the $550 million timing benefit is a warning: **don't extrapolate this quarter's beat into next quarter's results**.

### The Pipeline Question

Merck has been on a deal spree, acquiring or licensing assets to offset the Keytruda cliff. The **$400 million SciBrunch charge** is the latest example. The company is spending now to build the next generation of revenue.

Whether those bets pay off is the question that will determine Merck's stock price for the next five years. This quarter's beat buys credibility. It doesn't buy certainty.

---

## Frequently Asked Questions

### Did Merck beat earnings?

**Yes, decisively.** Adjusted EPS was **$2.49** vs. the $2.08 consensus. Revenue was **$18.09 billion** vs. $17.31 billion expected .

### Why did Merck raise guidance?

Because the quarter was stronger than expected, driven by Keytruda and the new Qlex shot. The company raised the midpoint of its EPS and revenue outlook, even while absorbing the $400 million SciBrunch charge .

### What is Keytruda Qlex and why does it matter?

It's the **subcutaneous (under-the-skin) version** of Keytruda. It generated **$830 million** in Q3, well above expectations. Merck is racing to shift patients to Qlex before the original IV Keytruda loses patent protection in 2028. Qlex has its own patent protection, which preserves the franchise .

### What is the $550 million timing benefit?

Q3 sales got a **$550 million boost** from favorable purchase timing in the U.S. Merck said this benefit will **fully unwind in Q4** for Keytruda and Winrevair, and mostly next year for vaccines. It's pulled-forward demand, not new demand .

### What happened to Januvia and Bridion?

Both drugs are facing **generic competition**. Januvia/Janumet sales fell **39%**, and Bridion dropped **67%** as cheaper copycats entered the U.S. market. That's the patent cliff in action—and a preview of what Keytruda will face in 2028 .

### What is the SciBrunch deal?

Merck signed a global licensing agreement with **SciBrunch**, a Chinese cancer drugmaker. The deal included a **$400 million upfront charge** (12 cents per share) that hit Q3 earnings. It's part of Merck's strategy to build its pipeline ahead of the Keytruda patent cliff .

### Should I buy Merck stock?

I can't give personalized investment advice. What I can tell you is that **the analyst consensus is generally positive**, the dividend is secure, and the Qlex strategy is working. But the patent cliff is real, the Q4 timing unwind will make comparisons harder, and the pipeline bets carry risk. The risk/reward depends on your time horizon and income needs.

---

## The Path Forward: What to Watch

### The Q4 Unwind

Merck said the $550 million timing benefit will reverse in Q4. Watch whether the company can still hit its raised guidance despite that headwind. If it does, the underlying business is stronger than the headline suggests.

### Keytruda Qlex Adoption

The $830 million quarter is impressive, but the real test is whether the growth continues. Watch the Q4 number and any commentary on how many patients are switching from IV to subcutaneous.

### The 2027 Outlook

Merck said it expects **modest revenue growth in 2027**, with Keytruda moderating and Bridion facing generics. Watch for more detail on the 2027 guidance and whether the pipeline can offset the declines.

### The Pipeline

Merck has been acquiring assets aggressively. Watch for updates on **sac-TMT** (the ADC with a PDUFA date of June 15, 2027) and other pipeline candidates . The patent cliff is coming. The pipeline is the answer.

---

## Conclusion: The Shot That Bought Time

Here's what I want you to take away from Merck's quarter.

Merck is facing the same cliff that every blockbuster drug company eventually faces: **the patent expires, the generics arrive, and the revenue disappears**. Keytruda is one of the most successful drugs in history, and in 2028, it starts to lose its exclusivity.

The Qlex shot is Merck's answer. By moving patients to a new formulation with its own patent protection, Merck can keep the franchise alive. The **$830 million** quarter proves the strategy is working.

But Merck isn't standing still. It's spending hundreds of millions on licensing deals, betting that the next generation of drugs will arrive before the current one fades. The **$400 million SciBrunch charge** is the price of that bet.

For patients, the message is hopeful: the drug you depend on may not disappear. For investors, the message is more nuanced: **the beat is real, but the timing quirk is a warning**. Q4 will be harder. 2027 will be harder still. The question is whether Merck's pipeline can outrun the cliff.

This quarter, Merck bought itself time. The clock is still ticking.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or medical advice. The author is not a licensed financial advisor or physician. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change. The author holds no position in any securities mentioned.

---

**Tags:** #Merck #MRK #Q3Earnings #Keytruda #KeytrudaQlex #PharmaStocks #StockMarketToday 

Lilly Just Beat Every Expectation on the Back of Mounjaro and Zepbound—But the Real Story Is the $4.57 Charge Nobody's Talking About

 Lilly Just Beat Every Expectation on the Back of Mounjaro and Zepbound—But the Real Story Is the $4.57 Charge Nobody's Talking About

**By [moonlight editory team ] | October 29, 2026 | 12-Minute Read**

---

## The Short Version (For the Busy American)

Eli Lilly just delivered one of the most dominant quarters in pharmaceutical history, and the market rewarded it immediately.

The Indianapolis-based drugmaker reported **third-quarter revenue of $24.4 billion**—up **38.6% year-over-year** and a staggering **$1.8 billion above** Wall Street's consensus estimate. Adjusted earnings per share came in at **$7.48**, beating expectations by roughly **13%** . The stock jumped more than **4%** in premarket trading Thursday .

The engine, as always, was the GLP-1 franchise. **Mounjaro generated $10.7 billion** in global sales, up **65%**, with international revenue nearly doubling. **Zepbound brought in $5.35 billion**, up **49%** . Together, those two drugs account for roughly **two-thirds of Lilly's entire revenue** .

But here's the twist that separates this quarter from a simple victory lap: **Lilly raised its revenue guidance by $5.5 billion—but actually lowered its full-year EPS guidance**. The culprit is a **$4.57 per share charge** tied to business development deals signed in the third quarter. The company spent billions buying up future pipeline assets, and that spending is now hitting the bottom line .

**The punchline:** Lilly is growing so fast that it can afford to buy its own future and still beat expectations. But the gap between its soaring revenue and its flat earnings guidance tells you something important: **the next phase of Lilly's story isn't about Mounjaro and Zepbound. It's about what comes after them.**

---

## The Numbers That Matter

Let's cut through the noise and get to what actually counts.

### The Q3 Beat

| Metric | Q3 2026 | Consensus | Beat |

|--------|---------|-----------|------|

| **Revenue** | **$24.4B** | $22.61B | **+7.9%** |

| **Adjusted EPS** | **$7.48** | $6.61 | **+13.2%** |

| **Mounjaro Revenue** | **$10.7B** | — | **+65% YoY** |

| **Zepbound Revenue** | **$5.35B** | — | **+49% YoY** |

| **Gross Margin** | **83.9%** | — | +1.0 pt YoY |

*Source: Lilly Q3 release, Yahoo Finance, SEC filing* 

The Mounjaro number is the headline. **$10.7 billion in a single quarter** for one drug is almost incomprehensible. International sales surged **93%**, driven by volume growth as Lilly expanded access in markets like China through the NRDL .

### The Guidance Nuance

Here's where it gets interesting.

**Revenue guidance was raised** from $85-87 billion to **$91-92 billion**—a $5.5 billion increase at the midpoint that blew past the $88.7 billion consensus .

**But EPS guidance was lowered** from $35.50-$36.50 to **$35.00-$36.00**. The company explained the math: underlying performance improved by **$4.07 per share**, but that gain was offset by **$4.57 per share** in acquired in-process research and development charges from Q3 business development activity .

Translation: Lilly spent money buying future drugs, and that spending is a one-time hit to this year's earnings. The underlying business is stronger than the guidance suggests.

### The Oral GLP-1 Miss

Not everything was perfect. **Foundayo**, Lilly's once-daily oral obesity pill, generated just **$184 million** in its first full quarter—well below the **$229-231 million** consensus estimate .

Foundayo competes directly with Novo Nordisk's oral obesity drug, which launched earlier this year. The miss suggests that while Lilly dominates the injectable market, the oral market is more contested—and patients may be sticking with the injectable products they know .

---

## The Human Touch: What This Means for Real Americans

Let me put this in terms that actually connect to your life.

### If You Own Lilly Stock

You've been on an extraordinary ride. A **$10,000 investment five years ago** would be worth roughly **$54,477 today**—an average annual return of **40.36%**. The S&P 500 over the same period would have turned that $10,000 into about **$17,940** .

Lilly became the **first healthcare company to reach a $1 trillion market cap**. The stock is up roughly **4%** on this quarter's results. But the guidance nuance is a reminder that the easy money may have been made—and the next phase depends on whether Lilly can diversify beyond Mounjaro and Zepbound.

### If You Take These Drugs

Mounjaro and Zepbound are changing lives. They're driving significant weight loss and blood sugar control for millions of Americans. The demand is so strong that Lilly is spending billions to expand manufacturing—new facilities in **Texas and Virginia** are under construction .

But the Foundayo miss is worth watching. If you're considering an oral GLP-1, the market is still evolving. Lilly's pill isn't the only option, and the competition with Novo Nordisk is just beginning.

### If You Care About Drug Prices

Here's the uncomfortable part. Lilly's revenue surged **38.6%**—but the company noted that **realized prices fell 15%** in the quarter. Volume grew **53%**, more than offsetting the price decline .

That means Lilly is selling more drugs at lower prices. For patients, that's good news—prices are coming down as volume scales. For Lilly, it means the growth story depends on **finding more patients**, not charging more per patient.

### The $4.57 Question

The $4.57 per share charge is the most important number in the report that nobody is talking about. It represents **billions of dollars** Lilly spent acquiring or licensing new drug candidates in Q3 .

That's what a company does when it knows its current blockbusters won't last forever. Mounjaro and Zepbound are generating enormous cash flow—and Lilly is plowing it back into the pipeline. The question is whether those bets pay off before the GLP-1 growth slows.

---

## Frequently Asked Questions

### Did Lilly beat earnings?

**Yes, decisively.** Adjusted EPS was **$7.48** vs. the $6.61 consensus. Revenue was **$24.4 billion** vs. $22.61 billion expected. Both were significant beats .

### Why did Lilly lower its EPS guidance if it beat the quarter?

Because of a **$4.57 per share charge** tied to acquired in-process research and development from business development deals signed in Q3. The company's underlying performance improved by **$4.07 per share**, but the acquisition charges offset that gain. Revenue guidance was raised, but EPS guidance was slightly lowered due to the one-time charge .

### How much did Mounjaro and Zepbound make?

**Mounjaro**: $10.7 billion in global revenue, up **65%**. **Zepbound**: $5.35 billion, up **49%**. Together, they represent roughly **two-thirds of Lilly's total revenue** .

### What happened with Foundayo?

Foundayo, Lilly's oral obesity pill, generated **$184 million** in Q3—well below the **$229-231 million** consensus estimate. It competes with Novo Nordisk's oral obesity drug, which launched earlier this year. The miss suggests the oral market is more competitive than the injectable market .

### Is Lilly still a buy?

I can't give personalized investment advice. What I can tell you is that **the analyst consensus is overwhelmingly bullish**, and the company's growth trajectory remains extraordinary. But the stock trades at a premium valuation, and the guidance nuance is a reminder that the next phase depends on pipeline execution, not just GLP-1 demand.

### What is the $900 million benefit in the quarter?

Lilly noted that Q3 included approximately **$900 million in benefits**, primarily from a **$410 million Jardiance milestone payment** and favorable adjustments to rebate and discount estimates. The company confirmed no additional Jardiance milestones will flow through in future quarters .

### What did the CEO say?

David Ricks, Lilly's chair and CEO: **"Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience"** .

### What's the biggest risk?

**Concentration.** Mounjaro and Zepbound are the engine of the entire company. If demand slows, if competition intensifies, or if pricing pressure accelerates, the growth story weakens. The $4.57 per share in business development spending is Lilly's attempt to diversify—but those bets take years to pay off.

---

## The Path Forward: What to Watch

### The Oral GLP-1 Market

Foundayo's slow start is a warning sign. Watch whether Lilly can gain traction against Novo Nordisk's oral offering—and whether the oral market cannibalizes the injectable market or expands it.

### The Pipeline Bets

Lilly spent billions on business development in Q3. Watch for announcements about those acquisitions and whether they translate into new drug approvals in 2027 and 2028.

### The Manufacturing Buildout

New facilities in Texas and Virginia are under construction. Watch for updates on capacity—and whether Lilly can meet demand without supply constraints.

### The Pricing Question

Realized prices fell 15% in the quarter. Watch whether that trend continues as Lilly prioritizes volume over price. For patients, lower prices are welcome. For investors, it's a margin question.

---

## Conclusion: The Trillion-Dollar Tightrope

Here's what I want you to take away from Lilly's quarter.

The company is executing at a level almost no pharmaceutical company has ever achieved. **$24.4 billion in quarterly revenue. $10.7 billion from a single drug. A $1.15 trillion market cap.** The GLP-1 franchise is one of the most successful drug launches in history, and it's still growing.

But Lilly isn't standing still. It's spending billions to buy the next generation of drugs, knowing that Mounjaro and Zepbound won't last forever. The $4.57 per share charge is the price of that preparation.

For American investors, the message is simple: **Lilly is still a growth story, but the story is changing**. The easy money from the GLP-1 boom has been made. The next phase depends on whether the pipeline bets pay off before the current blockbusters peak.

For American patients, the message is more hopeful: **the drugs are working, the prices are coming down, and the pipeline is full**. Lilly's dominance is being challenged by Novo Nordisk, which means more competition, more options, and eventually, lower prices.

Lilly just proved it can beat expectations while preparing for the future. The question is whether the future arrives before the growth slows.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or medical advice. The author is not a licensed financial advisor or physician. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change. The author holds no position in any securities mentioned.

---

**Tags:** #EliLilly #LLY #Q3Earnings #Mounjaro #Zepbound #GLP1 #ObesityDrugs #Diabetes #PharmaStocks